<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125394</url>
  </required_header>
  <id_info>
    <org_study_id>TCL/CSH/022019</org_study_id>
    <nct_id>NCT04125394</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of Hypertonic Sodium Chloride (NaCl 5%) Eye Drops Without Preservatives in Corneal Edema</brief_title>
  <official_title>Unicentric Clinical Trial on the Clinical Efficacy and Tolerance of the Treatment With an Ophthalmic Solution of Hypertonic Sodium Chloride (NaCl 5%) Without Preservatives in Patients Suffering From Symptomatic Corneal Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tiedra Farmacéutica SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Principe de Asturias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tiedra Farmacéutica SL</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corneal edema is frequently found in clinical practice as a common sign of acute corneal
      disease due to different etiologies that cause an accumulation of extracellular fluid in the
      cornea. The present unicentric clinical trial aims to evaluate the efficacy and tolerance of
      an ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in
      participants suffering from symptomatic corneal edema.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from Baseline in Visual acuity</measure>
    <time_frame>Baseline, Day 7 and Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Corneal Thickness</measure>
    <time_frame>Baseline, Day 7 and Day 28</time_frame>
    <description>Micrometers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with Treatment-Related Adverse Events (Objective Tolerance)</measure>
    <time_frame>Baseline, Day 7 and Day 28</time_frame>
    <description>Slit Lamp Examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Score in Subjective Tolerance Test</measure>
    <time_frame>Day 7 and Day 28</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Corneal Edema</condition>
  <arm_group>
    <arm_group_label>NaCl 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertonic sodium chloride (NaCl 5%) eye drops solution in single-dose, without preservatives, administered every 8 hours for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose</intervention_name>
    <description>Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container</description>
    <arm_group_label>NaCl 5%</arm_group_label>
    <other_name>Ocumax 5 eye drops solution in single-dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Clinical diagnosis of symptomatic corneal edema related to chronic epithelial,
             secondary to corneal dystrophies, controlled infectious and inflammatory pathologies
             and surgical trauma already resolved.

          -  No need for keratoplasty in the 6 months following the start of the study

        Exclusion Criteria:.

          -  Visual acuity less than 1/20 in both eyes

          -  Corneal edema caused by the following acute etiologies: trauma, infection,
             inflammation or Stevens-Johnson syndrome.

          -  Glaucoma or uncontrolled hypertension.

          -  Known allergy to any of the ingredients of the product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tiedra Farmaceutica</last_name>
    <phone>+34 91 643 41 40</phone>
    <email>info@tiedra.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá De Henares</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Cañones</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>corneal edema</keyword>
  <keyword>sodium chloride</keyword>
  <keyword>single-dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

